Ipratropium Bromide Inhalation Solution Rx
Generic Name and Formulations:
Ipratropium bromide 0.02% (500mcg in 2.5mL); for oral inhalation; preservative-free.
Various generic manufacturers
Indications for Ipratropium Bromide Inhalation Solution:
Bronchospasm associated with chronic bronchitis and emphysema.
500mcg orally by nebulization 3–4 times daily; separate doses by 6–8 hours.
Allergy to atropine or its derivatives.
Not for primary treatment of acute attack. Avoid eyes. Narrow-angle glaucoma. GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Caution with other anticholinergics.
Bronchitis, COPD exacerbation, dyspnea, headache, anticholinergic effects; paradoxical bronchospasm, hypersensitivity reactions.
Formerly known under the brand name Atrovent.
HFA (NO); soln (YES)
Inhaler—12.9g (200 inh); inhalation soln—contact supplier
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL